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Abstract
Objective: The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing dramatically affecting up to 30% of the
population worldwide. At present, treatment options are limited and pharmacological management of NAFLD has had
disappointing results. Some of the best available evidence to improve NAFLD concerns lifestyle modification.
Objective: To detect the degree of  weight reduction needed to improve the markers of  hepatic function and insulin
resistance in type-2 diabetics with NAFLD.
Methods: One hundred type-2 diabetic male patients with NAFLD were included into this study and divided into two
equal groups. Group (A) received aerobic exercise training in addition to diet regimen. Group (B) received no treatment
intervention.
Results: There was a 26.99%, 40.8%, 33.81%, 32.73%, 37.8% and 15 % reduction in mean values of Alkaline Phosphatase
(ALP), Alanine Aminotransferase  (ALT),   Aspartate Aminotransferase (AST), Gamma – Glutamyltransferase (GGT) and
Homeostasis Model Assessment-Insulin Resistance- index (HOMA-IR) and BMI respectively in group (A) at the end of
the study. While there were significant differences between mean levels of  the investigated parameters in group (A) and
group (B) after treatment.
Conclusion: About 15 % reduction in BMI is effective to improve the liver condition and insulin resistance in type-2
diabetics with NAFLD.
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Nonalcoholic fatty liver disease (NAFLD) is an
increasing condition associated with the sedentary
lifestyle and poor nutritional habits, with high
prevalence all around the World1. NAFLD is
considered the hepatic manifestation of the metabolic
syndrome, a cluster of  metabolic abnormalities
related to insulin resistance, including central obesity
and dyslipidemia 2. The imbalance in the metabolism
of fatty acids in conjunction with the adipose tissue,
liver tissue and systemic inflammation, are key factors
for the development of insulin resistance,
dyslipidemia and other cardiovascular risk factors
associated with the ‘nonalcoholic fatty liver disease’
(NAFLD)3.
Type 2 diabetes mellitus (T2DM) and
obesity are the two metabolic conditions more
closely associated with NAFLD and its progression
towards advanced liver disease4. Paralleling the
increasing prevalence of  obesity, NAFLD has
become common and potentially serious 5.They both
stem from alterations in insulin action (insulin
resistance), a metabolic state in which physiologic
concentrations of insulin produce a lower-than-
normal biologic response, or higher-than-normal
insulin concentrations are necessary to elicit a normal
metabolic response. Thus, any measure able to
modify overweight/obesity or a sedentary lifestyle,
as well as the associated defect(s) in insulin action
represents both a preventive measure and a treatment
option for NAFLD6.
          There is no proven treatment for
patients with NAFLD are currently available. Weight
reduction and lifestyle modifications with diet
changes and increased physical activity are usually
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recommended as the first step in the treatment of
patients with this condition. Achieving and maintaining
weight reduction may improve NAFLD, but the
results of several reports are inconsistent7. Studies
reporting the effect of weight reduction in NAFLD
to date have included small numbers of patients that
were treated for a short period of time8.
        The purpose of this study was to
investigate the degree of weight reduction needed
to improve the markers of hepatic function and




One hundred type-2 diabetic male patients with
NAFLD with body mass index (BMI) ranged from
30 to 35 Kg/m2 , their age ranged from 35 to 55
years , type 2 diabetic patients were selected
according to the criteria published by the American
Diabetes Association 9, free from  other liver ,
metabolic or genetic diseases. Participants were
included in this randomized controlled study and
divided into two equal groups; group (A) received
physical training combined with dietary measures.
The second group (B) received dietary measures only.
Participants were identified from a large number
of patients attending the Liver Clinic in King
Abdulaziz University Teaching Hospital, with a
histological diagnosis of  NAFLD. The diagnosis of
NAFLD was based on the following criteria: (1)
elevated aminotransferases (AST and/or ALT); (2)
liver biopsy showing steatosis in at least 10% of
hepatocytes; and (3) appropriate exclusion of liver
disease of  other aetiology including alcohol- or drug-
induced liver disease, autoimmune or viral hepatitis,
cholestatic or metabolic/genetic liver disease. These
other liver diseases were excluded using specific
clinical, biochemical, serologic tests radiographic and/
or histological criteria.
Exclusion criteria included: smoking;
hypertension, personal history of cardiovascular
diseases, thyroid disease and orthopedic problems
inhibiting treadmill training. This study was approved
by the Scientific Research Ethical Committee, Faculty
of  Applied Sciences, King Abdulaziz University.
Informed consent was obtained from all participants.
All participants were free to withdraw from the study
at any time. If any adverse effects had occurred, the
experiment would have been stopped, with this being
announced to the Human Subjects Review Board.
Chemical analysis
Blood samples were collected from the antecubital
vein at the beginning and end of the treatment
program. Subjects had blood drawn at the same
time in the morning on each occasion (between 8
and 10 AM). Subjects lay supine for 10 min prior to
the blood collection. 10 ml of blood was drawn
drawn into a tube containing few milliliters of
sodium citrate; plasma was separated from the blood
by centrifugation (120 × g for 15 min) at room
temperature. Markers of hepatic function (aspartate
aminotransferase, AST; alanine aminotransferase,
ALT; alkaline phosphatase, ALP and Homeostasis
Model Assessment-Insulin Resistance (HOMA) index
for insulin sensitivity was computed following this
equation: [fasting glycemia (mmol/L) X fasting insulin
(mIU/L)]/22.510 were measured by the colorimetric
enzymatic method using an automatic
spectrophotometer and respective kits for analysis
(Bioclin, Quibasa, Belo Horizonte, MG, Brazil).
Human insulin was measured with an insulin kit
(Roche Diagnostics, Indianapolis, IN, USA) using a
cobas immunoassay analyzer (Roche Diagnostics).
All samples were assayed in duplicate, and the mean
of  the paired results was determined.
Evaluation of anthropometric parameters
All measurements were performed at pretreatment
and after three months at the end of  the study. The
participants were measured whilst wearing their
undergarments and hospital gowns. Height was
measured with a digital stadiometer to the nearest
0.1 cm (JENIX DS 102, Dongsang, South Korea).
Body weight was measured on a calibrated balance
scale to the nearest 0.1 kg (HC4211, Cas Korea,
South Korea), and BMI was calculated as BMI =
Body weight / (Height)2.
The physical training program
The aerobic treadmill-based training program
(PRECOR 9.1/ 9.2, China) was set to 65%- 75%
of the maximum heart rate (HRmax) according to
a modified Bruce protocol. This rate was defined as
the training heart rate (THR).After an initial, 5-minute
warm-up phase performed on the treadmill at a
low load, each endurance training session lasted
30 minutes and ended with 5-minute recovery and
relaxation phase. All patients performed three weekly
sessions (i.e. a total of 36 sessions per patient over a
3-month period).
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The prescribed low calorie diet
The interview-based food survey was performed
for all patients by dieticians to specify previous food
habits and possible anomalies in dietary behavior.
The prescribed low calorie diet was balanced, with
15% as protein, 30 to 35% as fat and 50 to 55% as
carbohydrate, on average, in order to provide about
1200 Kilocalories daily for two months for whole
participants in this study.
Statistical analysis
The mean values of  ALP, ALT, AST, GGT, HOMA-
IR and BMI obtained before and after three months
in both groups were compared using paired “t”
test. Independent “t” test was used for the
comparison between the two groups (P<0.05).
Results
 This study was an attempt to investigate the degree
of weight reduction (a result that is needed to
improve the markers of hepatic function and insulin
resistance in type-2 diabetic patients with NAFLD.
However, no adverse effects occurred as the diet
regimen was low caloric diet not a very low caloric
diet and the aerobic exercise training was of
moderate intensity  ranged from 65%- 75% of
HRmax , so the data of all the participants were
available for analysis. There was a 26.99%, 40.8%,
33.81%, 32.73%, 37.8% and 15 % reduction in mean
values of  ALP, ALT, AST, GGT, HOMA-IR and
BMI respectively in group (A) at the end of  the study.
The mean values of  ALP, ALT, AST, GGT, HOMA-
IR and BMI were significantly decreased in group
received aerobic exercise training in addition to diet
regimen. While the results of group (B) received no
treatment intervention were not significant. Also,
there were significant differences between mean
levels of the investigated parameters in group (A)
and group (B) after treatment (table 1, 2, 3) (P<0.05).
Table 1: Mean value and significance of  the pre and post test values of  ALP, ALT, AST, GGT,
HOMA-IR and BMI in the training group
Mean + SD      t- value          P-value
Pre                       Post
ALP (U/L)      74.56 ± 9.32       58.71± 8.26         9.23                0.0015
ALT (U/L) 46.88 ± 5.41            33.28± 4.76         8.64               0.0013
AST (U/L)      45.98 ± 6.63             34.36 ± 5.11        9.15                0.0027
GGT(U/L) 28.63 ± 3.26            21.57 ± 3.1          7.34                0.0056
HOMA-IR 4.92 ± 2.78             3.57 ± 1.3           6.12                 0.0083
BMI (Kg / m2) 32.11±3.54             27.25 ±2.68         8.33          0.0094
ALT = Alanine aminotransferase              GGT= Gamma – glutamyltransferase
AST = Aspartate aminotransferase             ALP = Alkaline phosphatase    BMI= Body mass index
HOMA-IR = Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) index
Table 2: Mean value and significance of  the pre and post test values of  ALP, ALT, AST, GGT,
HOMA-IR and BMI in the control group
Mean + SD       t- value         P-value
Pre                             Post
ALP (U/L)           73.31 ± 8.92             73.68 ± 9.23      0.76              0.139
ALT (U/L) 47.22 ± 6.05             47.91 ± 6.75      0.85              0.144
AST (U/L)          46.16 ± 6.87              46.87 ± 7.24      0.49              0.172
GGT(U/L) 29.33 ± 3.76             30.01 ± 3.65      0.91              0.115
HOMA-IR 4.98 ± 2.51              5.13 ± 2.44        0.56              0.161
BMI           32.37 ± 3.92             32.64 ± 4.26      0.36            0.182
ALT = Alanine aminotransferase          GGT= Gamma – glutamyltransferase
AST = Aspartate aminotransferase         ALP = Alkaline phosphatase      BMI= Body mass index
HOMA-IR = Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) index
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Table 3: Mean value and significance of  the post test values of  ALP, ALT, AST, GGT, HOMA-IR
and BMI in the training and control groups
              Mean + SD                      t- value       P-value
Training group    Control group
ALP (U/L)        58.71± 8.26        73.68 ± 9.23 7.86 0.0062
ALT (U/L)        33.28± 4.76  47.91 ± 6.75         6.22      0.0074
AST (U/L)       34.36 ± 5.11      46.87 ± 7.24          7.07           0.0085
GGT(U/L)        21.57 ± 3.18  30.01 ± 3.65         5.93      0.0073
HOMA-IR         2.64 ± 1.37  5.13 ± 2.44            4.75           0.0091
BMI        27.25 ±2.68        32.64 ± 4.26          6.12    0.0088
ALT = Alanine aminotransferase               GGT= Gamma – glutamyltransferase
AST = Aspartate aminotransferase             ALP = Alkaline phosphatase    BMI= Body mass index
HOMA-IR = Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) index
Discussion
As the degree and rate of weight reduction needed
to improve the liver condition in patients with
NAFLD remains unknown. The aim of this study
was to detect the impact of weight reduction on
liver enzymes and insulin resistance in type-2 diabetic
patients with NAFLD received aerobic exercise
training in addition to diet regimen. Based on our
findings, a 15 % reduction in BMI and body weight
could be recommended as an initial therapeutic target
to improve the liver condition and insulin resistance
in type-2 diabetic patients with NAFLD. However,
the oral hypoglycemic agents who were received by
participants in both groups may have some effect
on insulin resistance, the more profound
improvement in insulin resistance in group (A) and
the little non significant changes in group (B) proved
that weight reduction was of great value to enhance
the therapeutic pharmacological effects of  oral
hypoglycemic agents.   Results of  this study supported
with many previous studies 11-21.
         Adherence to combined dietary restriction and
increased physical activity result in larger and
progressive weight loss that can be maintained
through the years11. Physical activity has an
independent and beneficial effect on fatty liver
12.Physical exercise promotes both weight loss, by
increasing the negative energy balance, and insulin
sensitivity, the determinant of  fatty liver, by
promoting triglyceride consumption in the skeletal
muscle tissue 13.Maintaining or increasing physical
activity provides health benefits for patients with fatty
liver, independent of changes in weight 14.
Weight, blood biochemical data as
aminotransferase, albumin, cholinesterase, total
cholesterol and fasting blood glucose values were
significantly decreased after a program of restricted
diet and exercise (walking or jogging) for a trial
period of 3 months in a previous study on twenty-
five obese patients with fatty liver 15.
A 10-week diet-plus-exercise and exercise-
only therapeutic lifestyle programs are effective for
improving anthropometric indices, insulin sensitivity,
ultrasound findings and physical fitness in ultrasound-
diagnosed NAFLD patients. However, the range of
improvement in patients on the diet-plus-exercise
program is more obvious than that in patients on
the exercise-only program. Moreover, the diet-plus-
exercise program resulted in significant improvement
in liver biochemistry, but the exercise-only program
did not. In summary, diet plus exercise is more
efficacious than exercise alone in the lifestyle
modification treatment of NAFLD 16.
In general, weight loss was shown to
improve liver histology17, whereas gradual weight
reduction and increased physical activity improves
liver enzymes15, 18, insulin sensitivity and quality of
life 19. In T2DM patients, moderate weight reduction
(8%) was shown to reduce liver fat that was
accompanied by a dramatic improvement in hepatic
insulin resistance, with return to normal suppression
of hepatic glucose production by insulin 20.
Regular exercise was also associated with
significantly greater ALT improvement and
normalization. For instance, exercise is known to
improve the sensitivity of muscle mass to insulin 21.
Furthermore, exercise that was not enough to reduce
body weight showed modest therapeutic effect in
reducing visceral fat and improving glucose
intolerance 22.
Energy restriction resulting in even modest
weight loss suppresses endogenous cholesterol
synthesis which leads to a decline in circulating lipid
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concentrations and increased insulin sensitivity that
contributes in improving lipoprotein profile after
treatment of obesity 23, 24. Low carbohydrate diet and
a low fat-diet may be useful in reducing the
intrahepatic triglyceride content 25, 26.Furthermore, 5%
or greater weight reduction was associated with
decrease in serum triglycerides, increase in serum
HDL-cholesterol and decrease in fasting blood
glucose.  This indicates that achieving and maintaining
5% weight reduction will improve not only the liver
condition but also several other components of the
metabolic (insulin resistance) syndrome18.
Conclusion
Based on our findings, a 15 % reduction in BMI is
effective to improve the liver condition and insulin
resistance in type-2 diabetic patients with NAFLD
to improve the liver condition.
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